This will be a multi-center, randomized, placebo-controlled parallel-group study to evaluate
nebulized fluticasone propionate (FP) dose response in adult subjects with partly controlled
and uncontrolled asthma. Individual participation will be approximately 16 weeks, including
12 weeks of double-blind treatment.